Pluri announced that its CDMO division has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. PluriCDMO will support Remedy Cell’s production team in the manufacturing of a clinical-grade Working Cell Bank and GMP batches of Remedy Cell’s drug candidate RC-0315, derived from mesenchymal stem cells, towards the launch of their Phase Ib clinical trial for the treatment of Idiopathic Pulmonary Fibrosis , a lethal, complex, progressive interstitial lung disorder with a median survival of 3.8 years.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PLUR:
- Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
- Pluri receives patent approval for 3D bioreactor technology
- Pluri appoints James Roosevelt, Jr. to advisory board
- Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
- Pluri CEO says entering 2024 with ‘significant momentum’
